Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial
Hannah Cohen(University College London Hospitals NHS Foundation Trust), David Isenberg(Regenerative Medicine Institute), Nicola Muirhead(University College London), María Laura Bertolaccini(St Thomas' Hospital), Beverley J. Hunt(Guy's and St Thomas' NHS Foundation Trust), Caroline J Doré(MRC Clinical Trials Unit at UCL), Ian Mackie(University College London), Munther A. Khamashta(The King's College), Maria Ruiz-Castellano(St Thomas' Hospital), Deepa J. Arachchillage(Imperial College Healthcare NHS Trust), Yvonne Sylvestre(University College London), Samuel J. Machin(University College London), Simon Clawson(University College London), Maria Efthymiou(University College London)
Cited by 404
Related Papers
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up
|Journal of the American College of Cardiology|2020|2.9k
The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition
|Critical Care|2016|1.5k
IRE1 Signaling Affects Cell Fate During the Unfolded Protein Response
|Science|2007|1.4k